

# CLINUVEL

## ASX ANNOUNCEMENT

Melbourne, Australia, 27 March 2025

ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY

### CLINUVEL renews share buy-back program

CLINUVEL will renew its share buy-back program for a further 12-months, allowing for the repurchase of up to 1,500,000 ordinary shares, representing approximating to 3.0% of its outstanding share capital.

“The Board is committed to ensuring all available tools are in place to achieve valuations that reflect CLINUVEL’s business and progress,” CLINUVEL’s Chair, Prof Jeffrey Rosenfeld said.

“In an uncertain macroeconomic environment, prudent cash management remains a priority. There may, however, be opportune moments to use capital to support our shareholders through an on-market share buy-back. The Board has closely monitored the buy-back program to date and decided that maintaining this option is in the best interests of the Company and shareholders,” Prof Rosenfeld added.

The timing, amount and pricing of any shares bought back, will depend on market conditions and other factors. CLINUVEL does not intend to be in the market at all times during the buy-back period, and any repurchases will be made at its discretion. The Company makes no assurance or guidance as to whether it will repurchase the full 3% of its issued capital under the buy-back program.

Please refer to the Appendix 3C for further information.

#### Further Statements to the Share Buy-Back

- duration of program to be 12 months from validation by ASIC;
- transactions in the Company’s securities will only be pursued if it is believed it will maximise the benefits of the on-market share buy-back program;
- transactions in the Company’s securities will be conducted within prescribed trading guidelines;
- there is no guarantee that the Company will buy-back any shares up to the intended maximum number of ordinary shares to be bought; and
- the Company reserves the right to suspend or terminate the buy-back at any time.

– END –

#### About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

#### Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

#### Investor Enquiries

### Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACËLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACËLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran's Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2024 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

### Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: [mail@clinuvel.com](mailto:mail@clinuvel.com)

**Australia (Head Office)**, Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

